SIAH2 protein expression is inversely correlated with the ER status and outcome to tamoxifen therapy in metastatic breast cancer patients

被引：1
|
作者：
van der Willik, K. D.
Timmermans, M. M.
Look, M. P.
Reijm, E. A.
van Deurzen, C. H. M.
den Bakker, M. A.
Westenend, P. J.
Martens, J. W. M.
Berns, E. M. J. J.
Jansen, M. P. H. M.
机构：
[1] Erasmus MC, Inst Canc, Rotterdam, Zuid Holland, Netherlands
[2] Maasstad Hosp, Rotterdam, Zuid Holland, Netherlands
[3] Pathol Lab, Dordrecht, Zuid Holland, Netherlands
来源：
CANCER RESEARCH | 2016年 / 76卷
关键词：
D O I：
10.1158/1538-7445.SABCS15-P5-08-51
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The predictive value of Her2/neu status on clinical outcome in tamoxifen-treated breast cancer patients
    Hanna, W
    Wong, JW
    Zubovits, J
    Trudeau, M
    LABORATORY INVESTIGATION, 2003, 83 (01) : 32A - 32A
  • [42] Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients
    Bo, Jiaqi
    Yu, Baohua
    Bi, Rui
    Xu, Xiaoli
    Cheng, Yufan
    Tu, Xi aoyu
    Bai, Qianming
    Yang, Wentao
    Shui, Ruohong
    CLINICAL BREAST CANCER, 2023, 23 (04) : 436 - 446
  • [43] Androgen receptor expression can predict benefit of tamoxifen treatment in patients with ER negative breast cancer
    Hilborn, Erik
    Gacic, Jelena
    Fornander, Tommy
    Skog, Lambert
    Nordenskjold, Bo
    Stal, Olle
    Jansson, Agneta
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [44] Discovery of new gene expression predictors for adjuvant tamoxifen outcome for breast cancer patients.
    Sgroi, DC
    Ma, XJ
    Ryan, P
    Wang, Z
    Younger, J
    Isakoff, S
    Smith, B
    Brugge, J
    Baer, TM
    Erlander, MG
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 835S - 835S
  • [45] Plasma thymidine kinase 1 activity and outcome of ER+ HER2− metastatic breast cancer patients treated with palbociclib and endocrine therapy
    Luc Cabel
    Dan Rosenblum
    Florence Lerebours
    Etienne Brain
    Delphine Loirat
    Mattias Bergqvist
    Paul Cottu
    Anne Donnadieu
    Anne Bethune
    Nicolas Kiavue
    Manuel Rodrigues
    Jean-Yves Pierga
    Marie-Laure Tanguy
    François-Clément Bidard
    Breast Cancer Research, 22
  • [46] Variation of ER status between primary and metastatic breast cancer and relationship to p53 expression
    Zheng, WQ
    Lu, J
    Zheng, JM
    Hu, FX
    Ni, CR
    STEROIDS, 2001, 66 (12) : 905 - 910
  • [47] A MAPK microRNA signature significantly associated with poor outcome and predictive of response to tamoxifen therapy in ER plus breast cancer
    Miller, Philip
    Clarke, Jennifer
    El-Ashry, Dorraya
    CANCER RESEARCH, 2015, 75
  • [48] INFLUENCE OF ESTROGEN-RECEPTOR (ER) STATUS ON RESPONSE OF METASTATIC BREAST-CANCER TO AMINOGLUTETHIMIDE THERAPY
    LAWRENCE, BV
    LIPTON, A
    HARVEY, HA
    WHITE, D
    SANTEN, RJ
    COX, CE
    SMART, EK
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1979, 20 (MAR): : 422 - 422
  • [49] Low Her2-expression as predictor of outcome in oestrogen-receptor (ER) positive metastatic breast cancer (MBC)
    Bergen, E.
    Berghoff, A. S.
    Rudas, M.
    Minichsdorfer, C.
    Dubsky, P.
    Sattlberger, C.
    Mader, R. M.
    Fitzal, F.
    Gnant, M.
    Zielinski, C. C.
    Preusser, M.
    Steger, G. G.
    Bartsch, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 262 - 263
  • [50] Ratio of 17HSD1 to 17HSD2 Protein Expression Predicts the Outcome of Tamoxifen Treatment in Postmenopausal Breast Cancer Patients
    Jansson, Agneta
    Delander, Lovisa
    Gunnarsson, Cecilia
    Fornander, Tommy
    Skoog, Lambert
    Nordenskjold, Bo
    Stal, Olle
    CLINICAL CANCER RESEARCH, 2009, 15 (10) : 3610 - 3616
12345